stockrow
Friday 6 November 2026
Export TLX’s income statement to Excel — free account
Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited’s revenue for fiscal 2025 (year ended December 2025) was $803.8 million, up 55.6% from fiscal 2024.
9.65
0.23
+2.44%
Follow TLX
Alert me
Telix Pharmaceuticals Limited (TLX) Net income
Telix Pharmaceuticals Limited's net income for fiscal 2025 was −$5.3M, compared with $37.9M in fiscal 2024. Over the twelve months to 30 June 2026 it was $31.7M. Telix Pharmaceuticals Limited ranks 43rd of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$5.3M | — |
| FY2024 | $37.9M | 1,748.61% |
| FY2023 | $2.1M | — |
Net income against peers
| Company | Net income |
|---|---|
| TLX Telix Pharmaceuticals Limited | $31.7M |
| ELVN Enliven Therapeutics, Inc. compare | −$105.9M |
| CELC Celcuity, Inc. compare | −$226.5M |
| DNLI Denali Therapeutics Inc. compare | −$314.4M |
| IDYA IDEAYA Biosciences, Inc. compare | −$420.0M |
| VRDN Viridian Therapeutics, Inc. compare | −$453.6M |
| DYN Dyne Therapeutics, Inc. compare | −$519.4M |
| VKTX Viking Therapeutics, Inc. compare | −$627.2M |
| TARS Tarsus Pharmaceuticals, Inc. compare | −$702.2M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item